Myrobalan Therapeutics, a Massachusetts-based biotech firm, has successfully completed a $24 million Series A funding round, featuring significant participation from Chinese investors. The financing was led by Shenzhen-based Co-win Ventures, with contributions from both new and existing investors, including Guan Zi Equity Investment (Li Shui) Partnership, 3E Bioventures Capital, and AB Magnitude Ventures Group.
Myrobalan is dedicated to developing central nervous system (CNS) therapeutics, particularly focusing on oral neurorestorative therapies. The company is advancing several preclinical compounds that are highly selective, brain-penetrant, and orally available. Leading the pipeline is a CSF1R-targeted IND-stage drug aimed at treating multiple sclerosis (MS), Alzheimer’s disease (AD), and amyotrophic lateral sclerosis (ALS). Additional targets in development include GPR17 and TYK2.- Flcube.com
